Navigation Links
Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks
Date:2/7/2014

Chevy Chase, MDAccording to a statement issued today by the Endocrine Society, the risks and benefits of testosterone therapy for older men with declining levels of the hormone need to be fully evaluated.

The statement comes in response to recent studies that have raised concerns about the safety of testosterone therapy in older men with a history of heart disease. Two retrospective analyses and one randomized trial supported by the Veterans Health Care System, and the National Institutes of Health found a higher rate of cardiovascular events in men who received testosterone and had preexisting heart problems. The U.S. Food and Drug Administration has announced it plans to evaluate the safety of testosterone therapy.

Testosterone is approved for the treatment of hypogonadism due to known diseases of the testes, pituitary and hypothalamus. Although the use of testosterone therapy is increasing, the treatment has not been approved for the treatment of age-related symptoms or the age-related decline of testosterone levels.

Important safety data are expected from the NIA's ongoing randomized trial examining testosterone in about 800 older men with unequivocally low testosterone levels and accompanying symptoms, including sexual and physical dysfunction. The trial's structure and careful monitoring of cardiovascular events will help provide important safety information.

The Society calls for the development of more large-scale randomized controlled trials to determine the true risks and benefits of testosterone therapy in older men.

In the statement, the Society recommends that middle-aged and older men who are considering testosterone supplementation for age-related declines should be informed of the potential cardiovascular risks. The Society also believes that it may be prudent not to administer testosterone therapy to men who have had a cardiovascular event (such as myocardial infarction, stroke or acute coronary syndrome) in the preceding six months.

In cases where men are being treated for hypogonadism as a result of known diseases of the testes, pituitary and hypothalamus, however, patients should consult their health care providers before making any changes to their medication regimen. The Society believes testosterone is generally safe and beneficial when used to treat young, hypogonadal men with these conditions. The Society's Clinical Practice Guideline on testosterone therapy in this population is available at http://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/FINAL-Androgens-in-Men-Standalone.pdf.


'/>"/>

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
301-941-0240
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
2. Simpler lifestyle found to reduce exposure to endocrine-disrupting chemicals
3. Imaging agents predict breast cancer response to endocrine therapy
4. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
5. Researchers craft tool to minimize threat of endocrine disruptors in new chemicals
6. UCLA study finds endocrine disorder is most common cause of elevated calcium levels
7. Endocrine Society announces 2014 Laureate Award winners
8. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
9. New American Chemical Society video: Behind the scenes tour of an electronic nose lab
10. The Gerontological Society of America Selects 2012 Fellows
11. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2018)... ... September 21, 2018 , ... Liz Dudek, Director of Health Care Affairs for ... Chapter meeting of the Florida Assisted Living Association (FALA) at 10:00 a.m. at Tessera ... will provide an overview of the success of the first five years of Florida’s ...
(Date:9/22/2018)... Calif. (PRWEB) , ... September 22, 2018 , ... ... and sizes. In fact, there are actually 29 different categories listed in section ... include charitable or religious organizations (often referred to as a 501(c)(3)), private foundations, ...
(Date:9/15/2018)... , ... September 14, 2018 , ... ... among other funding, full FY 2019 appropriations for Labor, Health and Human Services ... for the evidence-based Teen Pregnancy Prevention (TPP) Program, and $286.5 million for the ...
(Date:9/12/2018)... ... , ... De Novo Strategies for Getting Your Medical Device Approved:, What is ... – 3:00 p.m. ET, http://www.fdanews.com/denovostrategies , What’s the best route for ... What are the best practices to win approval? , These are some of the ...
(Date:9/12/2018)... , ... September 13, 2018 , ... Glori Blends will ... the industry leaders. , The expo will include vendors, presentations, panel discussions and a ... to educate attendees on their award winning products and assist customers with the best ...
Breaking Medicine News(10 mins):
(Date:9/24/2018)... ... , ... CloudMine, a HIPAA-compliant cloud-based health care platform solution ... award-winning Connected Health Cloud (CHC) platform. The latest version of the Connected Health ... as the introduction of new data visibility and governance features. This platform update ...
(Date:9/23/2018)... ... September 23, 2018 , ... ... California according to a study published in the prestigious International Journal of ... California: A Pilot Serological Study” was written by microbiologist Marianne Middelveen from ...
(Date:9/15/2018)... ... September 14, 2018 , ... EnviroLeather™ by LDI, a leader ... with SmithGroup, the Carto.graph collection is a graphic expression of mapping the San ... SmithGroup’s healthcare interior designer, Aileen Avila-Banaag to design the Carto.graph Collection. “I was ...
Breaking Medicine Technology: